Plain-English translation of NCT07047586 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combined with works better than alone for people with advanced liver cancer that has stopped responding to prior immunotherapy and bevacizumab treatment. You would be randomly assigned to receive either the two-drug combination or by itself. The goal is to see which approach helps patients live longer and control their cancer better.
Some patients with advanced liver cancer stop responding to standard immunotherapy treatments, and researchers believe that combining this medication with another type of immunotherapy might help patients whose cancer has progressed.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take plus or alone. The study involves regular clinic visits to receive your medication, have your blood drawn, and undergo imaging scans to monitor how your cancer is responding. You will be followed closely for safety, and the trial is expected to last until the research team gathers enough information to determine which treatment works better.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China